BioSpace News Archive

Celebrating the unstoppable entrepreneurs whose ambitions transform our world

KB103 is designed to deliver a full-length human type III collagen transgene via intradermal injection First in-human study will evaluate the safety and efficacy in acne scars and facial wrinkles Initial data from this study is anticipated in 2021 PITTSBURGH, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), today announced the initiation of the PEARL-1 study, a Phase 1 multi-dose, controlled clinical study of KB301 for the treatment of acne scars and facial

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it will be providing an update on its Ifenprodil idiopathic pulmonary fibrosis (IPF) and chronic cough Phase 2 human study, presented by Dr. Mark Williams, CSO and special guest panellist Dr. Martin Kolb. Dr. Martin Kolb is a leading global scientifi

Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a medical technology and digital health company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, today announced it will be participating in SLEEP 2020, the annual meeting of the American Academy of Sleep Medicine, which is taking place virtually on August 27-30, 2020. “We are looking forward to

Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified global medical aesthetics company, announced today that it has received approval from Japan’s Pharmaceutical and Medical Device Agency (”PDMA”) to market the Company’s entire OPUS line of breast implants in Japan. Sientra will market the complete portfolio of OPUS breast implants in Japan through its local partner Medical U&A, Inc. (“Medical U&A”), a leadi

DSG3-CAART achieved autoantibody elimination and resolution of blisters in active immune mouse model of pemphigus vulgaris Soluble autoantibodies demonstrated potential to enhance DSG3-CAART efficacy and did not demonstrate off-target toxicity DesCAARTes™ Phase 1 clinical trial actively recruiting patients PHILADELPHIA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T c

BioAge Plans Phase 2 Clinical trial in Hospitalized COVID-19 Patients Clinical development plan supported by potent inhibition of PGD2 DP1 Receptor by BGE-175 , activating immune-modulating mechanisms that result in 100% survival in aged preclinical models of coronavirus BioAge’s proprietary human aging data links activation of PGD2 DP1 signaling to increased risk of mortality and susceptibility to infections RICHMOND, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- BioAge Labs, Inc., a biot

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Namvar Kiaie to the Company’s Board of Directors, effective as of July 2, 2020. Aditxt’s

EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2), (the “Company” or “EXM”), an emerging bio-science company specializing in the production of unique cannabinoid formulations, is pleased to announce the advancement of its R&D operations at its Lisbon, Portugal, facility.

Study builds on extensive research showing that granulocyte-macrophage colony stimulating factor (GM-CSF) is needed for effective immune function in the lungs iLeukPulm Phase 2 Clinical TrIal Supported by $35 Million Contract from U.S. Department of Defense [25-August-2020] LEXINGTON, Mass. , Aug. 25, 2020 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a